Volume 7, Issue 1 (Autumn 2014)                   Iranian Journal of Blood and Cancer 2014, 7(1): 43-44 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
B A. Prevention from Doxorubicin Cardiotoxicity by Available Protective Agents in Iran. Iranian Journal of Blood and Cancer 2014; 7 (1) :43-44
URL: http://ijbc.ir/article-1-534-en.html
Prevention from Doxorubicin Cardiotoxicity by Available Protective Agents in Iran
Abdolkarimi B *
Abstract:   (5227 Views)
Doxorubicin, used in pediatric chemotherapy regimens, has cardiotoxic effects. Dexrazoxane is co-administrated with doxorubicin to prevent its cardiotoxicity. Here we have explored some alternative food or drugs to be used in absence of dexrazoxane since it’s not readily available in Iran at this time. Keywords: Pediatric, chemotherapy, doxorubicin, cardiotoxicity, dexrazoxane, Iran.
Keywords: Pediatric, chemotherapy, doxorubicin, cardiotoxicity, dexrazoxane, Iran.
Full-Text [PDF 520 kb]   (1520 Downloads)    
: Letter to Editor | Subject: Pediatric Hematology & Oncology
Received: 2015/01/14 | Accepted: 2015/01/14 | Published: 2015/01/14
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb